Risk factors for de novo hepatitis B virus reactivation in liver transplant recipient with long term HBIG treatment

被引：0
|
作者：
Umeda, Makoto
Marusawa, Hiroyuki
Ueda, Mikiko
Tanaka, Yuichi
Takada, Yasutsugu
Egawa, Hiroto
Uemoto, Shinji
Chiba, Tsutomu
机构：
来源：
GASTROENTEROLOGY | 2006年 / 130卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A787 / A787
页数：1
相关论文
共 50 条
  • [21] Risk factors for de novo hepatitis B during solid cancer treatment
    Sugimoto, Rie
    Furukawa, Masayuki
    Senju, Takeshi
    Aratake, Yoshihusa
    Shimokawa, Mototsugu
    Tanaka, Yuki
    Inada, Hiroki
    Noguchi, Tatsuya
    Lee, Lingaku
    Miki, Masami
    Maruyama, Yuji
    Hashimoto, Risa
    Hisano, Terumasa
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (24) : 6264 - 6273
  • [22] OCCULT HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT RECIPIENT.
    Cheung, Cindy K. Y.
    Lo, Chung-Mau
    Man, Kwan
    Lau, George K. K.
    Fun, Sheung-Tat
    Wong, John
    LIVER TRANSPLANTATION, 2008, 14 (07) : S237 - S237
  • [23] Recurrent Hepatitis B and D Virus Infection in a Liver Transplant Recipient
    Miyaaki, H.
    Tamada, Y.
    Hayashi, K.
    Taura, N.
    Miuma, S.
    Shibata, H.
    Soyama, A.
    Hidaka, M.
    Takatsuki, M.
    Eguchi, S.
    Nakao, K.
    TRANSPLANTATION PROCEEDINGS, 2017, 49 (01) : 175 - 177
  • [24] Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
    Rayes, N
    Seehofer, D
    Bechstein, WO
    Müller, AR
    Berg, T
    Neuhaus, R
    Neuhaus, P
    CLINICAL TRANSPLANTATION, 1999, 13 (06) : 447 - 452
  • [25] Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection
    Lora, Viviana
    Graceffa, Dario
    De Felice, Catia
    Morrone, Aldo
    Bonifati, Claudio
    DERMATOLOGIC THERAPY, 2019, 32 (03)
  • [26] De novo and apparent de novo hepatitis B virus infection after liver transplantation
    Roche, B
    Samuel, D
    Gigou, M
    Feray, C
    Virot, V
    Schmets, L
    David, MF
    Arulnaden, JL
    Bismuth, A
    Reynes, M
    Bismuth, H
    JOURNAL OF HEPATOLOGY, 1997, 26 (03) : 517 - 526
  • [27] HBIg-Induced Transient Hepatitis B Core Antibody in Liver Transplant Recipient: Misleading Serology Testing?
    Poowanawittayakom, Nongnooch
    Alhammadi, Ahmed
    Chimienti, Sonia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S857 - S857
  • [28] LONG-TERM RISK OF DE NOVO HEPATITIS B USING HBCAB POSITIVE LIVER GRAFTS IN ACCORDANCE TO THE GUIDELINES
    Dondossola, Daniele Eliseo
    Antonelli, Barbara
    Invernizzi, Federica
    Donato, Maria Francesca
    Fornoni, Gianluca
    Maggi, Umberto
    Rossi, Giorgio
    Caccamo, Lucio
    TRANSPLANT INTERNATIONAL, 2017, 30 : 460 - 460
  • [29] Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy
    Mei, Takanori
    Noguchi, Hiroshi
    Hisadome, Yu
    Kaku, Keizo
    Nishiki, Takehiro
    Okabe, Yasuhiro
    Nakamura, Masafumi
    TRANSPLANT INFECTIOUS DISEASE, 2020, 22 (02)
  • [30] Low Risk of Hepatitis B Virus (HBV) Recurrence after Withdrawal of Hepatitis B Immunoglobulin (HBIG) in a Liver Transplant(LT) Population on Oral Antivirals
    Agrawal, Nidhi
    Shechtel, Joanna L.
    Parpia, Tarina
    Fishbein, Thomas
    Shetty, Kirti
    HEPATOLOGY, 2012, 56 : 530A - 530A
12345